Continued propagation of the CRF19_cpx variant among HIV-positive MSM patients in Spain.
PMID: 29325134
2018
The Journal of antimicrobial chemotherapy
Abstract: Conclusions: We demonstrate that this variant has spread in Spain in recent years among young HIV-positive MSM and we note a recent expansion in southern Spain in patients who carry mutation G190A.
Abstract: We found a larger cluster that grouped nine patients from southern Spain (Malaga and Seville), of which six presented mutation G190A.
Emergence as an outbreak of the HIV-1 CRF19_cpx variant in treatment-naive patients in southern Spain.
Figure: Sequences presenting the G190A mutation are highlighted within the light grey shaded square.
Discussion: In this respect, more than half of our cohort possessed the G190A mutation associated with different levels of NNRTI resistance (intermediate resistance for efavirenz, potential low level resistance for etravirine, high level resistance for nevirapine, and low level resistance for rilpivirine).
Discussion: This subtype is associated with a high prevalence of cross-class primary resistance to NNRTI in our area, with more than half the cases presenting the G190A resistance mutation.
Discussion: Unlike the G190A mutation though, the above mentioned polymorphism only confers low-level resistance
Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes.
Result: For those on treatment (n = 14), 7 had the K103N mutations and 5 had the V106M or G190A mutations, and 2 and the K101E mutations.
Result: Overall, the number of FSWs with the K103N mutation was 68.9% (31/45), the K101E mutation was found in 6/45 (13.3%), the V106M mutation in 10/45 (22.2%), G190A in 5/45 (11.1%), and the NRTI mutation M184V was present in 13/45 (28.9%) of SWs.
Table: G190A
Upward trends of acquired drug resistances in Ethiopian HIV-1C isolates: A decade longitudinal study.
Result: At T1, the NNRTIs resistance associated mutations were detected at a lower frequency [K103N (n = 2), V106M, Y181S, Y188L, V90I, K101E and G190A (n = 1 each)].
Table: G190A
Discussion: Lastly, the study in one side identified an increasing common mutational pathways overtime with two thymidine non-analog (M184V and K65R) and three thymidine analog (D67N, K70R and K219E) major nucleoside reverse transcriptase inhibitor (
Prevalence of Pre-antiretroviral-Treatment Drug Resistance by Gender, Age, and Other Factors in HIV-Infected Individuals Initiating Therapy in Kenya, 2013-2014.
PMID: 29040633
2017
The Journal of infectious diseases
Abstract: PDR was defined as >=2% mutant frequency in a participant's HIV quasispecies at pol codons K103N, Y181C, G190A, M184 V, or K65R by oligonucleotide ligation assay and Illumina sequencing.
Community Based Antiretroviral Treatment in Rural Zimbabwe.
PMID: 28899102
2017
AIDS research and human retroviruses
Abstract: Seven participants had sequence data available, and five had drug resistance mutations, K65R, T69N, K101E, K103N, Y181C/I, M184V, and G190A.
Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128).
Result: For the NNRTIs, one or two DRM (either K103N, V106M or G190A) were the most common and were more prevalent in subjects that had been on treatment for >5 years (p < 0.05.
Result: The most dominant DRM against the reverse transcriptase inhibitors (RTI), were M184V (51.7%), K103N (50%), V106AM (20.6%), G190A (13.8%), D67N (13.8%), K65R (12.1%) and K219Q/E (12.1%.
HIV mutation literature information.
PMID: 
2018
The Journal of antimicrobial chemotherapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT